Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Belite Bio, Inc. ADR ( (BLTE) ) has issued an announcement.
On December 1, 2025, Belite Bio announced positive results from its Phase 3 DRAGON trial for Tinlarebant, a treatment for Stargardt disease. The trial demonstrated a significant reduction in retinal lesion growth, marking a potential breakthrough for a condition with no current approved treatments. The successful trial positions Belite Bio to file for regulatory approval in 2026, potentially offering new hope to over 50,000 affected individuals in the U.S. The findings underscore the company’s commitment to addressing unmet medical needs and could significantly impact the treatment landscape for retinal disorders.
The most recent analyst rating on (BLTE) stock is a Buy with a $154.00 price target. To see the full list of analyst forecasts on Belite Bio, Inc. ADR stock, see the BLTE Stock Forecast page.
Spark’s Take on BLTE Stock
According to Spark, TipRanks’ AI Analyst, BLTE is a Neutral.
Belite Bio faces significant financial challenges with no revenue and increasing losses, impacting its overall score. Technical indicators show neutral momentum, and valuation is unattractive with negative earnings. However, the earnings call highlights clinical advancements and financial stability, providing a positive outlook in the long term despite current financial difficulties.
To see Spark’s full report on BLTE stock, click here.
More about Belite Bio, Inc. ADR
Belite Bio, Inc. operates in the biotechnology industry, focusing on developing treatments for retinal degenerative diseases. The company is primarily engaged in advancing therapeutic candidates for conditions such as Stargardt disease, a genetic eye disorder that leads to vision loss.
Average Trading Volume: 90,338
Technical Sentiment Signal: Buy
Current Market Cap: $4.8B
Learn more about BLTE stock on TipRanks’ Stock Analysis page.